
EuroEspes S.A (EEP) | Financial Analysis & Statements
EuroEspes S.A. | Small-cap | Healthcare
EuroEspes S.A. | Small-cap | Healthcare
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Income Metrics
Balance Sheet Metrics
Total Assets
10.2M
Total Liabilities
4.0M
Shareholders Equity
6.2M
Debt to Equity
0.65
Cash Flow Metrics
Revenue & Profitability Trend
EuroEspes S.A Income Statement From 2019 to 2023
Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
---|---|---|---|---|---|
Revenue | 3.0M | 3.3M | 3.3M | 2.5M | 2.4M |
Cost of Goods Sold | 242.8K | 217.2K | 101.8K | 141.0K | 267.0K |
Gross Profit | 2.7M | 3.1M | 3.2M | 2.4M | 2.1M |
Gross Margin % | 91.8% | 93.4% | 96.9% | 94.4% | 88.8% |
Operating Expenses | |||||
Research & Development | - | - | - | - | - |
Selling, General & Administrative | - | 1.4M | 1.0M | 623.1K | - |
Other Operating Expenses | 1.6M | 1.6M | 1.2M | 753.6K | 990.0K |
Total Operating Expenses | 1.6M | 2.9M | 2.2M | 1.4M | 990.0K |
Operating Income | -1.4M | -956.6K | -247.4K | -351.0K | -826.7K |
Operating Margin % | -47.6% | -29.0% | -7.5% | -13.9% | -34.8% |
Non-Operating Items | |||||
Interest Income | - | - | 154.7K | 21 | - |
Interest Expense | 220.9K | 103.8K | 94.8K | 82.9K | 96.8K |
Other Non-Operating Income | - | - | - | - | - |
Pre-tax Income | -2.1M | -1.2M | -177.0K | -429.5K | -956.1K |
Income Tax | - | - | 6.5K | -18.1K | 384.2K |
Effective Tax Rate % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Net Income | -2.1M | -1.2M | -183.4K | -411.3K | -1.3M |
Net Margin % | -72.3% | -35.3% | -5.6% | -16.3% | -56.4% |
Key Metrics | |||||
EBITDA | -408.3K | -102.2K | 510.9K | 229.7K | -221.0K |
EPS (Basic) | - | €-0.10 | €-0.02 | €-0.04 | €-0.12 |
EPS (Diluted) | - | €-0.10 | €-0.02 | €-0.04 | €-0.12 |
Basic Shares Outstanding | - | 11608566 | 11597984 | 11573296 | 10547661 |
Diluted Shares Outstanding | - | 11608566 | 11597984 | 11573296 | 10547661 |
Income Statement Trend
EuroEspes S.A Balance Sheet From 2019 to 2023
Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
---|---|---|---|---|---|
Assets | |||||
Current Assets | |||||
Cash & Equivalents | 422.9K | 971.1K | 2.0M | 2.2M | 2.3M |
Short-term Investments | 2.5K | 2.5K | 17.2K | 17.6K | 20.5K |
Accounts Receivable | 248.0K | 374.1K | 322.1K | 183.5K | 189.3K |
Inventory | 342.8K | 475.0K | 549.8K | 431.6K | 354.7K |
Other Current Assets | - | - | - | - | - |
Total Current Assets | 1.1M | 2.0M | 2.9M | 3.0M | 3.0M |
Non-Current Assets | |||||
Property, Plant & Equipment | 10.4M | 10.5M | 10.0M | 9.9M | 9.9M |
Goodwill | 3.0M | 3.6M | 4.0M | 3.8M | 3.3M |
Intangible Assets | 3.0M | 3.6M | 4.0M | 3.8M | 3.3M |
Long-term Investments | 0 | 9.9K | 15.0K | 0 | - |
Other Non-Current Assets | -151 | - | 1 | - | -1 |
Total Non-Current Assets | 6.9M | 8.3M | 9.3M | 8.7M | 8.4M |
Total Assets | 7.9M | 10.2M | 12.3M | 11.7M | 11.4M |
Liabilities | |||||
Current Liabilities | |||||
Accounts Payable | 117.1K | 179.2K | 165.8K | 218.6K | 136.5K |
Short-term Debt | 4.0M | 1.8M | 810.5K | 859.6K | 1.2M |
Current Portion of Long-term Debt | - | - | - | - | - |
Other Current Liabilities | - | - | - | - | - |
Total Current Liabilities | 5.0M | 2.6M | 1.6M | 1.4M | 1.7M |
Non-Current Liabilities | |||||
Long-term Debt | 28.1K | 2.6M | 3.2M | 2.8M | 2.1M |
Deferred Tax Liabilities | 2.7K | 3.0K | 3.6K | 5.0K | 5.6K |
Other Non-Current Liabilities | - | -1.2M | - | - | - |
Total Non-Current Liabilities | 44.6K | 1.5M | 3.3M | 2.9M | 2.2M |
Total Liabilities | 5.0M | 4.0M | 4.8M | 4.3M | 3.9M |
Equity | |||||
Common Stock | 7.1M | 7.1M | 7.1M | 7.1M | 6.5M |
Retained Earnings | -2.1M | -1.1M | -183.4K | -411.3K | -1.3M |
Treasury Stock | 143.2K | 110.9K | 107.6K | 151.2K | 168.3K |
Other Equity | - | - | - | - | - |
Total Shareholders Equity | 2.9M | 6.2M | 7.4M | 7.4M | 7.4M |
Key Metrics | |||||
Total Debt | 4.0M | 4.4M | 4.0M | 3.6M | 3.3M |
Working Capital | -3.9M | -586.2K | 1.4M | 1.6M | 1.3M |
Balance Sheet Composition
EuroEspes S.A Cash Flow Statement From 2019 to 2023
Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
---|---|---|---|---|---|
Operating Activities | |||||
Net Income | -2.1M | -1.2M | -177.0K | -429.5K | -956.1K |
Depreciation & Amortization | - | - | - | - | - |
Stock-Based Compensation | - | - | - | - | - |
Working Capital Changes | 899.9K | -236.9K | -277.1K | -216.0K | 32.3K |
Operating Cash Flow | -1.0M | -2.2M | -1.1M | -825.0K | -987.2K |
Investing Activities | |||||
Capital Expenditures | -167.4K | -554.8K | -94.1K | -60.3K | -230.6K |
Acquisitions | - | - | - | - | - |
Investment Purchases | -557.5K | 0 | -560.0K | 0 | 0 |
Investment Sales | 10.1K | - | - | - | - |
Investing Cash Flow | -714.8K | -554.8K | -654.1K | -60.3K | -230.6K |
Financing Activities | |||||
Share Repurchases | -34.2K | -101.9K | -152.3K | -85.6K | -142.0K |
Dividends Paid | - | - | - | - | - |
Debt Issuance | 57.6K | 995.6K | 1.0M | 1.5M | 764.2K |
Debt Repayment | -57.0K | -634.9K | -687.5K | -1.2M | -1.1M |
Financing Cash Flow | -33.6K | 364.7K | 491.0K | 312.8K | -285.8K |
Free Cash Flow | 32.8K | -1.4M | -184.1K | -429.9K | -804.6K |
Net Change in Cash | -1.8M | -2.4M | -1.2M | -572.5K | -1.5M |
Cash Flow Trend
EuroEspes S.A Key Financial Ratios
Valuation Ratios
Price to Sales
2.12
Profitability Ratios
Profit Margin
91.78%
Operating Margin
-64.77%
Return on Equity
-73.83%
Return on Assets
-26.90%
Financial Health
Current Ratio
0.77
Debt to Equity
0.70
Per Share Data
Peer Financial Comparison
Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
---|---|---|---|---|---|---|
eep | 6.3M | - | - | -73.83% | 91.78% | 0.70 |
Clinica Baviera S.A | 698.2M | 18.17 | 7.83 | 46.33% | 13.51% | 70.72 |
Pangaea Oncology | 58.7M | - | 3.22 | -29.97% | -37.18% | 23.04 |
Grifols, S.A | 7.8B | 29.19 | 1.69 | 4.99% | 4.00% | 126.87 |
Laboratorios | 2.7B | 20.75 | 4.88 | 25.01% | 17.66% | 22.50 |
Almirall S.A | 2.2B | 102.60 | 1.51 | 1.45% | 2.02% | 26.47 |
Financial data is updated regularly. All figures are in the company's reporting currency.